Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... that it has priced an underwritten registered offering of ... of $9.00 per share, and granted the underwriters in ... an additional 585,000 shares of its common stock. The ... offering is expected to close on May 6, 2015, ...
(Date:5/1/2015)... Investor-Edge has initiated coverage ... GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ), ... research report on Genetic Technologies can be accessed ... 2015, the NASDAQ Composite ended at 4,941.42, down ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has commenced an underwritten ... expects to grant the underwriters a 30-day option to ... shares of common stock offered in the public offering. ... can be no assurance as to whether or when ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Ill., May 28 Abbott will present,at the ... June 10, 2008. Thomas C. Freyman, executive vice ... presentation on the,company at 3:20 p.m. Central time., ... will be accessible through,Abbott,s Investor Relations Web site ...
... May 28 National Stem Cell,Holding, Inc. (OTC: NHGI ... to,change its name to Proteonomix, Inc. The change will ... Cohen, President/CEO, stated: "Our new name reflects the fact,that ... stage and,commencing the commercialization of our technologies. These technologies,relate ...
... -, - Three Poster Presentations on the Hydrogel ... Inc. (Amex: ULU ),today announced that at the upcoming ... 28th to June 1, 2008, Dr. John St. John, ULURU,s,Vice ... with the presentation of three posters., The title of ...
Cached Biology Technology:National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 2National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 3ULURU Inc. to Present at the 8th World Biomaterials Congress 2ULURU Inc. to Present at the 8th World Biomaterials Congress 3
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... Federal government changes to Canada,s fisheries legislation "have ... of the country,s fish species, scientists at the ... a new study. The changes were "politically ... government policy and are inconsistent with ecosystem-based ...
... Professor Catherine Pickering, said the Griffith study looked at ... be dispersed through horse manure. The findings have been ... . "We reviewed 15 studies on seed germination ... America, three from Australia and one study each from ...
... , Nov. 7, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... its ongoing Phase 1 trial of KB004, an anti-EphA3 ... session at the 55 th American Society of ... trial of KB004 is a multi-center, dose-escalation study evaluating ...
Cached Biology News:Changes to fisheries legislation have removed habitat protection for most fish species in Canada 2Saddling up against the threat to our National Parks 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 3KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 4KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 5
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
... The ScriptCap™ 2'-O-Methyltransferase converts Cap 0 ... mRNA. The Cap 1 structure has been ... by up to 50%. This improvement is ... the ScriptCap™ m7G Capping System as well ...
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: